Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01028560 · ClinicalTrials.gov registry record · Phase 1
Allergy Immunotherapy for the Reduction of Asthma
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT01028560 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 58 participants.
The verdict
NCT01028560, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing asthma and allergy related disease in children who had multiple episodes of wheezing and who are at high risk for developing persisting asthma. These risks include a history of asthma in the parents, allergies to environmental allergens (such as dust mite, cockroach or mouse) and other allergic diseases such as eczema or food allergies. Allergy Immunotherapy is not new and has been practiced for many years to treat asthma and environmental allergies in older children and adults, but has not yet been systematically studied in young children.
Interventions
- OTHER Standard of care
- BIOLOGICAL Allergen extracts (subcutaneous injections)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-10 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01028560
The ClinicalTrials.gov registry entry for NCT01028560 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.
NCT01028560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01028560 about?
NCT01028560 is a clinical study titled "Allergy Immunotherapy for the Reduction of Asthma". In this clinical study we aim to determine the effect of allergy immunotherapy in decreasing asthma and allergy related disease in children who had multiple episodes of wheezing and who are at high risk for developing persisting asthma. These risks include a history of asthma in the parents, allergi...
What is the current status of trial NCT01028560?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2008-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01028560?
The interventions under investigation include: Standard of care (OTHER), Allergen extracts (subcutaneous injections) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01028560?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.